Search AUPH
Aurinia Pharmaceuticals Inc.
Nasdaq · CIK 1600620
Last close15.83
Daily change-0.12 (-0.75%)
10 Years gain+388.58%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
AUPH · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
91.0Momentum
100.0Acceleration
100.0Confidence
91.0Annual Revenue8
Quarterly Revenue35
Annual CFO8
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth24.0 / 25
Quality17.7 / 25
Capital Efficiency20.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics9.3 / 10
Forward Indicators5.0 / 5
Signals
Gross margin expansionGross margin improved by 4.1593 percentage points.
Operating leverageOperating margin improved by 28.3979 percentage points.
ROIC expansionROIC improved by 20.2288 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 2.9056%.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Key Metrics
Revenue Growth TTM19.76%OK
Revenue CAGR 3Y28.3%OK
Gross Margin95.81%OK
Operating Margin48.39%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC33.2%OK
Incremental Operating Margin 3Y180.94%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-2.91%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $283.06M | $250.39M | $104.91M | $135.66M | n/a | 88.46% | 37.06% | n/a | 17.15% | 138.7M |
| 2025 FY Dec 31, 2024 | $235.13M | $206.89M | -$4.69M | $44.39M | n/a | 87.99% | -1.99% | n/a | -1.16% | 146.19M |
| 2025 FY Dec 31, 2023 | $175.51M | $161.37M | -$91.69M | -$33.46M | n/a | 91.94% | -52.24% | n/a | -22.62% | 143.24M |
| 2024 FY Dec 31, 2022 | $134.03M | $128.37M | -$111.47M | -$79.53M | n/a | 95.77% | -83.17% | n/a | -31.52% | 141.92M |
| 2023 FY Dec 31, 2021 | $45.61M | $44.51M | -$180.74M | -$157.69M | n/a | 97.61% | -396.31% | n/a | -74.59% | 129.37M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $311.51M | sum latest 4 fiscal quarters Revenue | OK | 0001600620-26-000017, 0001600620-26-000049 |
| Revenue Growth TTM | 19.76% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001600620-26-000017, 0001600620-26-000049 |
| Revenue CAGR 3Y | 28.3% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001600620-26-000017 |
| Revenue CAGR 5Y | 41.38% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001600620-26-000017 |
| Gross Profit CAGR 3Y | 24.95% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001600620-26-000017 |
| Operating Income Growth | 189.85% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001600620-26-000017, 0001600620-26-000049 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 95.81% | Gross Profit / Revenue | OK | 0001600620-26-000017, 0001600620-26-000049 |
| Operating Margin | 48.39% | Operating Income / Revenue | OK | 0001600620-26-000017, 0001600620-26-000049 |
| ROIC | 33.2% | NOPAT / Average Invested Capital | OK | 0001600620-26-000017, 0001600620-26-000049 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001600620-26-000062 |
| Current Ratio | 5.42x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $2.33 | Revenue / Diluted Shares | OK | 0001600620-26-000017, 0001600620-26-000049 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |